Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.46B, +16.7% YoY · Filed Oct 29, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.5 billion and net income of $2.2 billion. Free cash flow was $271.2 million. As of Sep 30, 2026 it held $3.6 billion in cash and investments and $249.4 million in total debt.
Revenue
$1.46B
+16.7% vs year-ago quarter
Net income
$2.17B
+640.5% vs year-ago quarter
Operating cash flow
$340.99M
+14.9% vs year-ago quarter
Free cash flow
$271.15M
-4.8% vs year-ago quarter
EPS
$15.72
+634.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
133.94M
+1.4% vs year-ago quarter
Net cash
$3.34B
Q3 FY2026
Operating margin
19.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALNY (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1178670
- Former names
- ALNYLAM PHARMACEUTICALS INC (until Jul 2, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | $1.1B | $1.2B | $773.7M |
| Operating income | $345.8M | $231.4M | $131.7M | $368.0M | -$16.2M |
| Net income | $2.2B | $164.5M | $111.5M | $292.7M | -$72.2M |
| Diluted EPS | $15.72 | $1.21 | $0.82 | $2.14 | -$0.55 |
| Operating cash flow | $341.0M | $397.2M | $217.7M | $296.9M | $127.8M |
| Free cash flow | $271.2M | $340.7M | $194.4M | $284.7M | $113.5M |
| Total assets | $8.0B | $5.6B | $5.0B | $4.9B | $4.6B |
| Total liabilities | $4.4B | $4.2B | $4.2B | $4.6B | $4.3B |
| Stockholders' equity | $3.6B | $1.4B | $789.2M | $580.2M | $555.3M |
| Cash and investments | $3.6B | $3.3B | $2.9B | $2.7B | $2.9B |
| Total debt | $249.4M | $256.4M | $270.6M | $268.2M | $270.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Nov 5, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 20, 2026 |
All 1002 Alnylam Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.